drug
discoveri
tradit
reli
either
serendipit
observ
classic
exampl
would
sir
alexand
fleme
discoveri
antibacteri
properti
penicillin
screen
natur
synthet
compound
combin
medicin
chemistri
see
overview
sourc
new
drug
highthroughput
highcont
screen
remain
indispens
drug
discoveri
process
convent
method
begin
give
way
ration
approach
util
avail
knowledg
threedimension
structur
drug
target
see
structurebas
drug
design
use
protein
structur
drug
discoveri
inform
gener
experiment
employ
biophys
method
xray
crystallographi
nuclear
magnet
reson
nmr
spectroscopi
theoret
util
experiment
deriv
structur
relat
macromolecul
gener
homolog
model
drug
target
see
protein
crystallographi
bionuclear
magnet
reson
compar
model
drug
target
protein
method
xray
crystallographi
product
gener
experiment
deriv
structur
biolog
macromolecul
approxim
nonredund
macromolecular
structur
sequenc
ident
deposit
protein
data
bank
pdb
time
write
determin
xray
crystallographi
eclips
biophys
method
combin
eg
nmr
spectroscopi
cryoelectron
microscopi
neutron
diffract
electron
diffract
see
research
collaboratori
structur
bioinformat
protein
data
bank
owe
great
number
technolog
advanc
field
xray
crystallographi
recent
year
mani
review
chapter
method
certain
maintain
domin
posit
structurebas
drug
design
sbdd
see
structurebas
drug
design
use
protein
structur
drug
discoveri
recent
estim
underscor
valu
xray
crystal
structur
drug
discoveri
process
averag
cost
million
requir
success
round
lead
identif
investig
new
drug
file
reduc
estim
structur
central
util
discoveri
process
largest
cost
reduct
stem
increas
qualiti
lead
candid
number
differ
pharmacophor
seri
design
aid
structur
inform
consid
great
valu
structur
rel
cost
xray
structur
determin
nearli
neglig
elucid
novel
solubl
target
averag
bacteri
human
hand
success
xray
crystal
structur
determin
integr
membran
protein
repres
largest
class
human
drug
target
particularli
recalcitr
crystal
cost
million
dollar
see
divers
versu
focu
choos
target
therapeut
area
ongo
develop
field
solubl
membran
protein
crystal
pois
reduc
attrit
rate
averag
cost
xray
structur
determin
come
year
macromolecular
crystallographi
ration
drug
design
histor
perspect
ace
like
carboxypeptidas
probabl
carri
posit
charg
group
interact
carboxytermin
carboxyl
moieti
ligand
activesit
zn
ace
carboxypeptidas
suitabl
locat
polar
carbonyl
group
substrat
scissil
peptid
bond
metal
like
coordin
anion
succin
moieti
dbenzylsuccin
acid
case
carboxypeptidas
virtu
ace
dipeptidyl
carboxypeptidas
activ
distanc
posit
charg
carboxylbind
site
activesit
zn
greater
correspond
distanc
carboxypeptidas
length
approxim
one
amino
acid
addit
spacer
would
therefor
need
incorpor
ace
inhibitor
natur
occur
peptid
ace
inhibitor
teprotid
isol
venom
brazilian
pit
viper
carri
prolin
cterminu
suggest
featur
critic
preserv
nonpeptid
inhibitor
well
arm
simpl
pencilsketch
cushman
ondetti
set
creat
potent
nonpeptid
ace
inhibitor
first
compound
succinyllprolin
inde
prove
specif
inhibitor
ace
howev
slightli
activ
explor
differ
structur
modif
simpl
methyl
succinyl
moieti
found
increas
inhibitori
potenc
one
order
magnitud
attempt
improv
bind
affin
compound
steer
decis
explor
role
inhibitor
probabl
zn
bind
moieti
replac
succinyl
carboxyl
group
sulfhydryl
function
figur
reduc
inhibit
constant
ic
addit
three
order
magnitud
result
compound
captopril
market
tradenam
capoten
turn
potent
oral
acespecif
antihypertens
receiv
fda
approv
earli
becam
squibb
first
billiondollar
drug
nearli
three
decad
later
recent
crystal
structur
determin
ace
inhibitor
complex
final
confirm
despit
ace
bear
littl
overal
structur
similar
carboxypeptidas
origin
pencilandpap
model
aceinhibitor
bind
remark
accur
figur
cushman
ondetti
semin
work
repres
landmark
field
sbdd
principl
stage
xray
crystallographi
project
within
sbdd
program
typic
repres
follow
mileston
satisfactori
overexpress
purif
solubil
target
macromolecul
reproduc
crystal
target
form
suitabl
highresolut
xray
data
analysi
collect
highqual
xray
diffract
data
unligand
target
andor
target
ligand
complex
success
phase
determin
product
highqual
structur
model
crystallographydriven
lead
discoveri
andor
lead
optim
see
one
challeng
aspect
crystallographi
project
design
initi
gene
construct
code
protein
interest
subsequ
gene
express
well
purif
character
recombin
gene
product
also
repres
one
timeconsum
stage
sbdd
program
figur
milligram
quantiti
protein
crystallographi
drug
discoveri
pure
protein
typic
mg
routin
need
screen
suffici
number
crystal
condit
order
gener
initi
crystal
hit
past
small
number
deoxyribonucl
acid
dna
construct
would
gener
subsequ
test
express
host
cell
level
solubl
recombin
protein
produc
would
assay
polyacrylamid
gel
electrophoresi
page
process
conduct
sequenti
individu
gene
construct
best
use
produc
protein
downstream
crystal
trial
recent
technolog
advanc
made
possibl
rapidli
gener
test
multipl
gene
construct
parallel
figur
flow
chart
illustr
typic
genetocryst
bottleneck
mileston
sbdd
program
probabl
success
exponenti
relat
number
independ
proteintarget
variant
screen
diversif
emphas
stage
gene
construct
design
choic
express
system
select
affin
tag
avail
biochem
biophys
bioinformat
data
exploit
design
deletiontrunc
mutant
achiev
first
major
mileston
commonli
regard
obtain
pure
homogen
monodispers
highli
solubl
sampl
one
recombin
protein
sampl
fail
meet
qualiti
criteria
often
rescu
implement
feedback
loop
incorpor
differ
screen
optim
procedur
highthroughput
solubl
screen
extens
crystal
screen
fail
produc
initi
crystal
hit
conting
pathway
follow
involv
modif
protocol
sitedirect
mutagenesi
direct
evolut
domain
map
ration
deoxyribonucl
acid
construct
design
vast
amount
uncertainti
go
design
initi
gene
construct
structur
inform
use
whenev
possibl
design
process
avail
structur
homolog
ortholog
paralog
rich
sourc
inform
regard
domain
boundari
unstructur
loop
region
need
consid
design
crystalliz
target
see
research
collaboratori
structur
bioinformat
protein
data
bank
multidomain
protein
exhibit
high
degre
conform
flexibl
might
preclud
crystal
trim
target
compact
form
consist
catalyt
core
repres
logic
strategi
particularli
purpos
sbdd
recent
exampl
pertain
approach
includ
studi
kinas
domain
cabl
work
bifunct
catalyt
domain
bacteri
stringent
respons
factor
relaspot
proteolyt
map
fulllength
protein
subsequ
analysi
sdspage
use
techniqu
identifi
stabl
domain
typic
fulllength
protein
digest
panel
proteas
sampl
analyz
either
fix
time
point
differ
proteas
concentr
variabl
time
point
fix
proteas
concentr
protein
also
digest
presenc
known
ligand
inhibitor
sinc
ligandinduc
order
unstructur
region
may
lead
uniqu
digest
map
suggest
altern
possibl
dna
construct
design
character
stabl
fragment
ntermin
sequenc
mass
spectrometri
subsequ
carri
provid
framework
gene
construct
optim
recent
year
seen
explos
use
bioinformat
tool
aid
gene
construct
design
predict
disord
region
given
protein
sequenc
see
bioinformat
gene
protein
sequenc
databas
includ
foldindex
disembl
drippr
r
maccallum
unpublish
data
globplot
iupr
pondr
prelink
ronn
suit
util
differ
method
eg
neural
network
support
vector
machin
disord
predict
biannual
casp
critic
assess
techniqu
protein
structur
predict
challeng
constantli
evalu
rank
accuraci
variou
structur
predict
program
note
signific
progress
field
curat
databas
contain
inform
protein
partial
complet
disord
disprot
develop
perhap
one
excit
recent
develop
promis
greatli
assist
process
gene
construct
design
deuteriumexchang
mass
spectrometri
dxm
figur
method
produc
highresolut
map
order
disord
region
along
protein
sequenc
requir
microgram
solubl
protein
detect
disord
segment
littl
four
residu
use
combin
ligand
inhibitor
demonstr
success
produc
crystalliz
fragment
figur
schemat
depict
hydrogendeuteriumexchang
ms
dxm
procedur
aid
design
dna
construct
identifi
unstructur
region
protein
target
establish
initi
protein
fragment
map
protein
interest
incub
deuterium
oxid
lead
rapid
exchang
solvent
expos
amid
nitrogen
rapid
denatur
acid
quench
solut
deuter
sampl
proteolyz
brief
exposur
immobil
pepsin
proteolyt
fragment
separ
hplc
analyz
ms
disord
region
local
interpret
amid
hydrogendeuterium
exchang
map
protein
crystallographi
drug
discoveri
affin
chromatographi
find
right
tag
aid
purif
recombin
protein
target
usual
fuse
affin
tag
ad
cterminu
target
sequenc
necessari
insert
within
sequenc
maxim
crystal
potenti
recombin
target
emphasi
place
diversif
select
affin
tag
vast
number
affin
tag
avail
ideal
choic
depend
numer
factor
includ
prefer
tag
locat
tag
size
rang
residu
kda
desir
balanc
auxiliari
tag
characterist
gene
express
solubl
tag
protein
eas
purif
overal
puriti
elut
sampl
secret
express
oligohistidin
tag
histag
often
first
choic
rel
low
cost
small
size
eas
use
incorpor
histag
permit
simpl
onestep
purif
use
immobil
metalaffin
chromatographi
imac
resin
ni
nitrilotriacet
second
polish
step
use
sizeexclus
ionexchang
chromatographi
often
need
elimin
contamin
host
protein
natur
affin
imac
resin
subsequ
tag
remov
desir
eg
suspect
tag
might
interf
crystal
protein
activ
vector
qiagen
xa
avail
allow
incorpor
cleavabl
tag
contain
flank
proteas
recognit
site
recent
compar
studi
differ
affin
tag
tout
use
strepii
tag
trpserhisproglnphegluli
bind
modifi
streptavidincoupl
matrix
streptactin
accord
studi
strepii
tag
afford
much
higher
puriti
tag
compar
cost
larg
affin
tag
contain
fusion
protein
maltosebind
protein
thioredoxin
glutathionestransferas
improv
fold
enhanc
solubl
coupl
target
moreov
grow
number
chimer
targetfus
crystal
structur
report
suggest
fusion
protein
use
tool
crystal
gene
construct
design
choos
best
express
system
equal
troublesom
procedur
util
escherichia
coli
express
host
long
method
choic
provid
fairli
robust
easi
mean
produc
recombin
protein
minim
expens
despit
advantag
point
larg
percentag
case
cytosol
protein
encod
bacteri
archaeal
genom
appear
insolubl
express
e
coli
product
eukaryot
protein
particularli
problemat
posttransl
modif
phosphoryl
glycosyl
requir
proper
fold
activ
recombin
target
eukaryot
express
system
offer
advantag
capabl
phosphoryl
glycosyl
recombin
protein
variou
degre
baculoviru
system
particularli
suitabl
highthroughput
need
sbdd
program
insect
cell
typic
durabl
mammalian
cell
recent
yeast
pichia
pastori
genet
engin
human
form
full
complement
nglycosyl
machineri
develop
pave
way
largescal
product
recombin
human
protein
immedi
applic
rang
protein
therapeut
sbdd
gener
express
vector
clone
newer
clone
system
includ
novagen
ptriex
invitrogen
echo
invitrogen
gateway
kit
advantag
allow
test
multipl
affin
tag
e
coli
insect
cell
minim
subclon
product
misfold
protein
often
allevi
util
chaperon
foldas
factori
screen
method
coexpress
target
stabil
bind
partner
possibl
newer
express
system
novagen
duet
coexpress
vector
allow
simultan
express
eight
protein
cell
multipl
case
illustr
benefit
bindingpartn
coexpress
one
protein
compon
insolubl
unstabl
express
exampl
complex
polyomaviru
intern
protein
pentamer
major
capsid
protein
success
prepar
crystal
coexpress
compon
e
coli
coexpress
essenti
obtain
complex
sinc
fragment
found
insolubl
express
independ
proteintocryst
mileston
repres
formid
challeng
sbdd
biolog
macromolecul
complex
dynam
entiti
uniqu
set
physicochem
properti
univers
recip
exist
crystal
purifi
sampl
may
seem
first
intrins
noncrystalliz
great
deal
time
resourc
may
requir
find
optim
set
crystal
condit
construct
suitabl
variant
produc
highqual
crystal
sever
strategi
acceler
phase
sbdd
pipelin
outlin
follow
subsect
solubl
optim
first
hurdl
purif
crystal
success
purif
protocol
establish
frequent
case
final
elut
buffer
inappropri
initi
crystal
trial
moreov
unusu
observ
solubl
recombin
target
standard
elut
buffer
much
lower
protein
concentr
normal
requir
crystal
usual
mg
ml
even
though
franz
hofmeist
observ
differenti
solubl
protein
variou
salt
year
ago
larg
amount
subsequ
research
conduct
phenomenon
protein
solubl
optim
still
regard
somewhat
trialanderror
scienc
protein
complex
biolog
polyelectrolyt
fairli
unpredict
solubl
characterist
order
anion
cation
accord
gener
abil
stabil
structur
protein
refer
hofmeist
seri
ammonium
sulfat
commonli
use
precipit
protein
crystallographi
tend
stabil
protein
fold
state
drive
solut
guanidinium
chlorid
opposit
tendenc
differenti
effect
salt
one
import
variabl
screen
search
condit
enhanc
solubl
overexpress
protein
cosolv
addit
modul
protein
solubl
direct
interact
protein
modifi
surround
water
structur
also
worthwhil
explor
particularli
recalcitr
protein
glycerol
enhanc
solubl
without
denatur
protein
deterg
improv
solubl
bind
hydrophob
surfac
patch
protein
addit
cosolv
small
organ
molecul
polyval
ion
sugar
polyhydr
alcohol
also
help
improv
protein
solubl
stabil
differ
effect
screen
ideal
solubl
buffer
composit
therefor
complex
multiparamet
puzzl
lindwal
cowork
one
first
group
approach
problem
develop
sparsematrix
solubl
screen
could
use
crude
cell
extract
carri
recombin
protein
screen
empir
design
base
known
solubl
enhanc
produc
favor
result
laboratori
protein
appear
otherwis
insolubl
standard
lysi
purif
buffer
altern
solubl
screen
method
employ
dynam
light
scatter
photometr
analysi
develop
specif
crystallographi
applic
protein
puriti
gener
regard
critic
determin
success
crystal
cours
alway
except
rule
protein
exhibit
propens
crystal
even
presenc
high
level
impur
earliest
account
success
protein
crystal
friedrich
report
growth
blood
crystal
earthworm
earthworm
hemoglobin
upon
slow
dehydr
raw
blood
sampl
inde
mani
crystal
specimen
suppli
semin
macromolecular
xray
studi
earli
coax
crude
biolog
mixtur
exampl
laboratori
wit
remark
propens
one
glycoprotein
isozym
crystal
equal
mixtur
two
differ
form
ruleofthumb
howev
protein
puriti
regard
utmost
stringenc
prepar
sampl
crystal
trial
purifi
protein
sampl
free
possibl
macromolecular
contamin
protein
dnarna
complex
carbohydr
etc
also
chemic
conform
homogen
exhibit
monodispers
size
distribut
free
denatur
speci
microheterogen
may
preclud
advers
affect
crystal
autom
assess
puriti
carri
highthroughput
sdspage
matrixassist
laser
desorpt
ioniz
maldi
mass
spectrometri
dynam
light
scatter
dl
measur
use
verifi
sampl
dispers
method
proven
effect
predict
tool
assess
crystalliz
macromolecul
estim
one
studi
much
protein
exhibit
monodispers
size
distribut
light
scatter
experi
crystal
use
standard
condit
sparsematrix
crystal
screen
posttransl
modif
ptm
major
sourc
heterogen
protein
least
differ
kind
ptm
eg
glycosyl
methyl
phosphoryl
sthiolat
etc
known
affect
characterist
molecular
weight
charg
solubl
modifi
protein
although
ptm
may
small
modif
may
serv
physiolog
role
drastic
impact
overal
conform
protein
crystal
standpoint
differ
modifi
form
perceiv
entir
foreign
particl
thu
similar
advers
effect
crystal
process
chromatograph
method
enzymat
treatment
mutagenesi
help
reduc
elimin
heterogen
glycosyl
particularli
problemat
sourc
heterogen
eukaryot
express
system
use
neg
influenc
attach
oligosaccharid
crystalliz
glycoprotein
presum
stem
elev
surfac
entropi
due
conform
flexibl
oligosaccharid
chain
well
differ
glycan
chain
length
branch
sugar
composit
remov
attach
oligosaccharid
enzymat
deglycosyl
suggest
way
overcom
problem
inde
sever
report
emphas
import
complet
deglycosyl
obtain
suitabl
diffract
crystal
complet
remov
asparaginelink
nlink
oligosaccharid
peptidenglycosidas
pngase
f
pngase
often
use
also
caus
deamid
asparagin
residu
aspart
acid
experi
howev
leav
innermost
sugar
residu
attach
protein
may
offer
addit
possibl
sugarmedi
crystalcontact
format
differ
deglycosyl
strategi
select
versu
complet
deglycosyl
therefor
devis
figur
exampl
select
ndeglycosyl
partial
digest
might
attempt
select
endoglycosidas
endo
f
f
endo
h
leav
innermost
nacetyl
glucosamin
glcnac
nlink
diacetylchitobios
glycan
core
attach
modifi
asn
case
glcnac
fucosyl
combin
treatment
afucosidas
might
warrant
unfortun
enzym
compar
pngase
f
pngase
remov
olink
glycan
serthr
residu
monosaccharid
must
sequenti
trim
seri
exoglycosidas
gal
galnac
core
remain
point
oglycosidas
use
remov
core
structur
without
chemic
modifi
serthr
residu
modif
core
structur
often
block
action
oglycosidas
may
requir
use
addit
glycosidas
neuraminidas
note
nonspecif
galactosidas
b
galactosidas
use
hydrolyz
galactos
core
glycan
leav
olink
galnac
attach
serthr
therebi
provid
altern
complet
sugar
remov
mutagenesi
suitabl
altern
enzymat
chromatograph
approach
gener
homogen
sampl
crystallograph
studi
exampl
substitut
asn
serthr
asnxaaserthr
sequon
prevent
nglycosyl
heterogen
phosphoryl
problem
instanc
express
kinas
insect
cell
enzymat
treatment
alkalin
phosphatas
phage
l
protein
phosphatas
use
success
obtain
complet
dephosphoryl
protein
crystallograph
studi
altern
mutat
serthror
tyrphosphoryl
site
elimin
heterogen
phosphoryl
altogeth
phosphoryl
play
critic
modulatori
role
target
protein
activ
phosphoryl
conform
might
interest
sbdd
case
gener
phosphoryl
conform
often
accomplish
replac
phosphoryl
serthr
residu
asp
glu
electroneg
side
chain
carboxyl
moieti
act
phosphat
mimic
microheterogen
isoelectr
heterogen
overcom
addit
purif
step
ionexchang
chromatographi
prepar
isoelectr
focus
techniqu
potenti
impact
microheterogen
protein
crystalliz
exemplifi
work
prongay
colleagu
crystal
complex
human
immunodefici
viru
capsid
protein
antigenbind
fragment
fab
work
recombin
purifi
homogen
chromatograph
separ
distinct
isoelectr
speci
one
abl
crystal
complex
fab
moreov
differ
crystal
form
fab
complex
could
obtain
differ
isoelectr
speci
fab
use
combin
crystalliz
fraction
recent
success
stori
employ
sever
method
describ
preced
section
express
structur
determin
truncat
deglycosyl
form
human
ace
test
tace
truncat
form
tace
lack
ntermin
residu
ctermin
transmembran
domain
express
presenc
nbutyldeoxynojirimycin
aglucosidas
inhibitor
express
mutant
tace
treat
endoglycosidas
h
select
remov
innermost
glcnac
residu
nglycosyl
site
although
express
low
shown
homogen
sdspage
fulli
activ
enzymat
assay
produc
crystal
diffract
resolut
led
longawait
structur
elucid
human
ace
complex
captopril
relat
antihypertens
describ
previous
chapter
pave
way
design
nextgener
inhibitor
figur
glycosyl
site
asnxaaserthr
mutat
systemat
replac
asn
gln
two
asngln
mutant
exhibit
higher
express
level
produc
crystal
isomorph
construct
although
resolut
good
anoth
relev
success
stori
involv
ration
reengin
anticanc
target
human
urokinas
crystallograph
studi
preliminari
crystal
urokinas
complex
inhibitor
diffract
resolut
yet
structur
solv
discov
activ
site
effect
shield
tight
intermolecular
pack
crystal
unfortun
pack
arrang
preclud
diffus
small
molecul
inhibitor
urokinas
activ
site
crystal
soak
method
use
initi
crystal
structur
guid
disord
highli
flexibl
polypeptid
region
judg
miss
electron
densiti
high
atom
temperatur
protein
crystallographi
drug
discoveri
factor
delet
gene
construct
moreov
free
cy
residu
expos
truncat
mutat
ala
addit
asngln
point
mutat
introduc
remov
nglycosyl
site
result
modifi
urokinas
term
microurokinas
subsequ
crystal
betterdiffract
crystal
form
suitabl
highthroughput
soak
experi
ration
drug
design
preced
section
dealt
differ
strategi
improv
crystal
probabl
overcom
heterogen
unfortun
realiti
often
pain
dictat
protein
even
purest
monodispers
homogen
form
simpli
wo
nt
crystal
recalcitr
type
fruitless
screen
thousand
upon
thousand
crystal
condit
cover
wide
expans
crystal
space
galvan
truth
result
mani
structur
genom
initi
around
world
confirm
major
protein
propens
crystal
astonishingli
narrow
rang
crystal
condit
consequ
grow
emphasi
screen
protein
target
variabl
protein
crystal
exampl
either
homologortholog
screen
sitedirect
mutagenesi
direct
evolut
chemic
mean
overal
probabl
crystal
target
exponenti
relat
number
protein
variant
util
assum
complet
independ
variant
overal
crystal
probabl
p
would
ave
n
p
ave
averag
probabl
crystal
one
n
variant
exampl
variant
target
chanc
crystal
variant
construct
overal
probabl
success
crystal
would
nearli
wayn
hendrickson
colleagu
first
systemat
analyz
crystal
probabl
enhanc
differ
protein
modif
multipl
combin
thereof
specif
target
envelop
glycoprotein
type
human
immunodefici
viru
previous
resist
crystal
explor
differ
deglycosyl
protocol
substitut
differ
surfac
loop
tripeptid
linker
glyalagli
produc
nand
ctermin
delet
mutant
reduc
conform
heterogen
use
differ
protein
ligand
receptor
fab
conform
sensit
monoclon
antibodi
success
grow
six
differ
type
crystal
differ
variant
one
ternari
complex
fab
human
neutral
monoclon
antibodi
determin
resolut
valu
use
homolog
crystal
screen
purpos
pioneer
decad
ago
john
kendrew
whose
initi
unsuccess
attempt
crystal
hors
heart
myoglobin
rescu
choos
sperm
whale
altern
sourc
materi
anoth
piec
semin
work
herman
watson
colleagu
use
protein
differ
sourc
crystal
enzym
glycolyt
pathway
systemat
variat
speci
origin
also
instrument
crystal
transcript
initi
tatabind
protein
recent
structur
proteom
data
corrobor
notion
show
inclus
homolog
protein
target
drastic
increas
crystal
success
rate
classic
set
paper
demonstr
effect
iter
structurebas
drug
discoveri
use
target
homolog
agouron
group
design
potent
antitumor
agent
target
human
thymidyl
synthas
use
crystalliz
e
coli
enzym
surrog
extens
approach
exemplifi
sbdd
select
cyclindepend
kinas
cdk
inhibitor
effort
obtain
crystal
design
inhibitor
unsuccess
merck
scientist
mutat
atpbind
pocket
crystalliz
homolog
creat
activesit
mimic
approach
result
success
design
inhibitor
recent
sever
acut
respiratori
syndrom
sar
outbreak
group
abl
integr
structur
data
obtain
main
proteinas
human
coronaviru
transmiss
gastroenter
corona
viru
molecular
model
biochem
analys
propos
deriv
inhibitor
distantli
relat
human
rhinoviru
proteinas
would
promis
lead
candid
design
antisar
drug
target
sar
coronaviru
main
proteinas
crystal
screen
homolog
fail
gener
hit
direct
evolut
approach
dna
shuffl
may
provid
necessari
breakthrough
figur
dna
shuffl
method
reli
homolog
recombin
pcr
reassembl
gene
fragment
multipl
parent
gener
crossov
point
high
sequenc
ident
procedur
gener
vast
librari
chimera
rapidli
screen
parallel
express
solubl
activ
sequenc
variant
meet
exceed
solubl
activ
criteria
undergo
crystal
trial
strategi
recent
paid
keenan
colleagu
implement
direct
evolut
program
engin
glyphos
nacetyltransferas
gat
superenzym
confer
glyphos
resist
transgen
plant
initi
attempt
crystal
three
wildtyp
gat
enzym
presenc
absenc
ligand
fail
produc
crystal
suitabl
structur
determin
overcom
bottleneck
multipl
round
dna
shuffl
carri
three
wildtyp
gat
gene
conjunct
highthroughput
screen
identifi
gat
chimera
decent
express
strong
enzymat
activ
high
solubl
eight
randomli
chosen
gat
variant
met
criteria
select
librari
contain
exchang
amino
acid
content
rel
wildtyp
enzym
util
crystal
procedur
wildtyp
enzym
spars
matrix
screen
conduct
presenc
absenc
ligand
two
eight
gat
chimera
produc
suitabl
crystal
crystal
structur
one
solv
surprisingli
result
crystal
structur
show
exchang
region
shuffl
gat
variant
involv
crystal
contact
format
ortholog
dnashuffl
chimera
may
exhibit
multipl
region
sequenc
variabl
protein
surfac
could
provid
uniqu
area
crystal
pack
singl
point
mutat
often
suffici
drastic
enhanc
crystalliz
target
perhap
earliest
exampl
demonstr
effect
method
ration
genet
engin
crystal
contact
human
h
ferritin
czech
physiologist
vilem
laufberg
note
ferritin
could
crystal
situ
ad
droplet
concentr
cadmium
sulfat
fresh
slice
hors
spleen
crystal
structur
hors
spleen
ferritin
rat
liver
ferritin
recombin
rat
lchain
ferritin
crystal
presenc
cdso
reveal
intermolecular
crystal
pack
via
doubl
cd
bridg
pair
aspart
glutamin
side
chain
neighbor
ferritin
molecul
form
ligand
metal
ion
human
hrich
ferritin
hand
immedi
form
amorph
precipit
upon
addit
cd
even
low
concentr
sequenc
comparison
reveal
human
h
ferritin
contain
lysin
place
cd
coordin
glutamin
residu
construct
lysgln
mutant
recombin
human
ferritin
larg
welldiffract
crystal
isomorph
hors
rat
ferritin
obtain
surprisingli
crystal
could
grown
presenc
ca
although
subsequ
structur
determin
reveal
two
ca
ion
form
ident
intermolecular
coordin
arrang
cd
hors
rat
ferritin
gener
util
metal
ion
organometal
compound
induc
macromolecular
crystal
growth
form
metalmedi
crystal
contact
overst
grow
number
success
stori
document
fact
continu
fill
literatur
practic
use
metal
ion
protein
crystal
date
far
back
john
j
abel
perhap
fortuit
first
use
zn
obtain
rhombohedr
crystal
insulin
laboratori
zn
remain
dival
cation
choic
crystal
addit
screen
exampl
includ
zn
mediat
crystal
macrophag
infect
potenti
protein
legionella
pneumophila
human
carbon
anhydras
th
unpublish
figur
emphas
howev
zn
best
crystal
addit
everi
protein
provid
enough
protein
sampl
avail
parallel
screen
differ
metal
salt
recommend
illustr
studi
examin
influenc
variou
dival
cation
crystal
isoleucinevalinebind
protein
leucinespecif
bind
protein
led
protein
crystallographi
drug
discoveri
observ
differ
metal
promot
differ
crystal
form
cd
produc
best
result
subsequ
studi
histidinebind
protein
salmonella
typhimurium
also
found
optim
metal
concentr
crystal
fell
within
narrow
rang
yet
imposs
predict
priori
type
metal
organometal
complex
concentr
rang
mmm
suitabl
crystal
given
protein
howev
remark
propens
zn
exhibit
wide
array
coordin
geometri
geometri
without
addit
weak
interact
broad
rang
potenti
protein
ligand
function
asp
glu
cy
mainchain
carbonyl
ctermin
carboxyl
togeth
util
figur
zn
mediat
crystal
drug
target
exemplifi
gener
util
metal
crystal
addit
screen
orthogon
view
crystal
lattic
crystal
human
carbon
anhydras
th
unpublish
data
crystallograph
asymmetr
unit
contain
two
monom
highlight
blue
two
zn
ion
involv
crystal
contact
format
depict
orang
sphere
tight
crystal
pack
promot
intermolecular
metalbridg
visibl
appar
b
orthogon
view
crystal
lattic
tetragon
crystal
macrophag
infect
potenti
protein
mip
legionella
pneumophila
case
dinuclear
zn
crystalcontact
bridg
catalyt
domain
symmetryrel
monom
otherwis
loos
pack
crystal
environ
case
presenc
zn
crystal
buffer
mandatori
crystal
c
variou
coordin
state
ligat
geometri
observ
zn
protein
crystal
state
addit
decor
weaker
longrang
interact
denot
plu
two
exampl
zn
mediat
crystal
contact
observ
high
resolut
th
unpublish
data
top
exampl
zn
establish
tetrahedr
crystal
contact
involv
ctermin
carboxyl
moieti
phe
side
chain
symmetryrel
monom
bottom
exampl
illustr
squarepyramid
zn
crystalcontact
ligat
ident
hisasp
residu
adjac
monom
water
molecul
occupi
apic
posit
multiplewavelength
anomal
dispers
phase
method
make
logic
first
choic
metaladdit
crystal
screen
consid
figur
pfizer
group
recent
propos
engin
carboxyl
protein
surfac
residu
asp
glu
protein
crystal
strategi
enabl
zn
mediat
crystal
contact
sinc
origin
work
lawson
cowork
human
hchain
ferritin
rapidli
grow
number
exampl
appear
mutat
protein
crystal
wildtyp
counterpart
classic
exampl
serendip
dictat
crystalliz
bacteri
chaperonin
groel
crystal
two
mutat
accident
incorpor
pcr
eleg
studi
ernest
villafranca
group
agouron
nonconserv
surfac
residu
human
thymidyl
synthas
ration
mutat
residu
alter
polar
charg
result
point
mutant
alter
crystal
behavior
gener
crystalliz
wildtyp
protein
crystal
uniqu
condit
produc
novel
crystal
form
higher
qualiti
use
inhibitor
soak
studi
analog
studi
roch
group
point
mutant
e
coli
dna
gyras
b
subunit
produc
similar
improv
crystalliz
crystal
qualiti
mindboggl
number
possibl
present
consid
sitedirect
mutagenesi
tool
crystal
new
target
rais
fundament
question
site
protein
sequenc
chosen
mutagenesi
kind
mutat
produc
best
result
part
strategi
remain
trialanderror
natur
rel
pauciti
empir
data
subject
still
leav
much
answer
exampl
solubl
crystal
screen
differ
hydrophobicli
point
mutant
catalyt
domain
hiv
integras
led
crystal
mutant
anoth
case
obtain
diffractionqu
crystal
mycobacteri
outer
membran
channel
possibl
prepar
dozen
point
mutant
either
within
zone
interspeci
sequenc
variat
predict
surfac
region
mutant
produc
crystal
diffract
resolut
point
mutat
wildtyp
human
leptin
produc
solubl
protein
crystal
allow
structur
determin
mutant
cyclophilin
gave
crystal
diffract
resolut
becom
clear
point
real
consensu
work
best
howev
recent
work
zygmunt
derewenda
group
illustr
consist
effect
incorpor
mutat
reduc
conform
surfac
entropi
underli
concept
stem
idea
surfac
residu
high
conform
entropi
creat
entrop
shield
prevent
format
stabl
intermolecular
interact
requir
crystal
contact
format
therefor
select
replac
conform
labil
surfac
residu
small
amino
acid
ala
could
reduc
entrop
penalti
crystal
contact
format
region
lysin
glutam
residu
identifi
good
candid
mutagen
replac
usual
locat
protein
surfac
side
chain
typic
character
high
conform
entropi
disfavor
protein
protein
interfac
hypothesi
emphat
valid
mutat
work
rhogdi
human
rhospecif
gdp
dissoci
inhibitor
sever
mutant
construct
contain
one
four
lysala
andor
gluala
exchang
subject
crystal
trial
almost
mutant
exhibit
alter
crystal
properti
sever
new
crystal
form
obtain
one
doublemut
produc
crystal
diffract
resolut
crystal
structur
determin
differ
mutant
reveal
mutat
epitop
particip
directli
crystal
contact
format
surfac
engin
strategi
sinc
produc
success
result
number
protein
current
trend
involv
make
multipl
mutat
within
short
lysglurich
cluster
recent
exampl
approach
toward
sbdd
provid
work
merck
scientist
investig
tyrosin
kinas
domain
insulinlik
growth
receptor
anticanc
target
crystal
unphosphoryl
apo
form
kinas
domain
diffract
resolut
resolut
low
highthroughput
structurebas
lead
optim
overcom
hurdl
three
differ
multipl
mutant
prepar
second
doublemut
produc
highqual
crystal
diffract
resolut
event
solubl
mutant
protein
critic
compromis
altern
mutat
polar
residu
less
conform
entropi
andor
smaller
size
eg
lysarg
lysasp
also
help
promot
crystal
concept
ration
design
protein
crystal
extend
wingren
colleagu
shown
possibl
replac
short
stretch
residu
bstrandcontain
protein
socal
pack
cassett
crystal
pack
motif
promot
crystal
gener
specif
crystal
pack
interact
mutat
work
function
integr
mutant
protein
need
evalu
prior
sbdd
direct
evolut
approach
produc
solubl
crystalliz
target
recent
emerg
power
altern
sitedirect
mutagenesi
method
allow
larg
mutant
librari
gener
errorpron
pcr
dna
shuffl
mutant
express
green
fluoresc
protein
gfp
fusion
visibl
assay
solubl
proper
fold
great
advantag
gfpbase
direct
evolut
approach
compar
ration
surfaceengin
elimin
guesswork
relat
mutant
design
sampl
mutat
space
much
effici
way
yang
cowork
demonstr
superior
util
gfpbase
direct
evolut
obtain
solubl
crystalliz
mutant
protein
mycobacterium
tuberculosi
mutant
gener
gfpbase
direct
evolut
solubl
least
mg
ml
compar
wildtyp
protein
express
e
coli
insolubl
inclus
bodi
import
observ
rais
author
crystallograph
studi
underli
contribut
individu
mutat
toward
enhanc
solubl
tripl
mutant
appear
involv
combin
alter
intrins
solubl
fold
kinet
like
would
much
difficult
imposs
ration
engin
solubl
mutant
quickli
effect
altern
strategi
deserv
consider
embark
timeconsum
approach
ortholog
screen
ration
surfac
engin
direct
evolut
perhap
even
final
recours
event
method
fail
chemic
modifi
target
protein
prior
crystal
reduct
alkyl
protein
sampl
formaldehyd
dimethylamineboran
complex
dmab
proven
success
chemic
treatment
strategi
establish
thu
far
crystal
recalcitr
sampl
although
techniqu
origin
use
improv
qualiti
poorli
diffract
crystal
use
tool
de
novo
crystal
pioneer
ivan
rayment
structur
determin
myosin
subfrag
methyl
protocol
gener
util
subsequ
publish
net
consequ
treatment
dimethyl
solventaccess
lysin
side
chain
well
ntermin
amino
group
result
charg
modifi
protein
chang
howev
isoelectr
point
may
shift
slightli
surfaceentropyreduc
mutagenesi
believ
crystalliz
chemic
modifi
target
may
enhanc
result
reduc
side
chain
entropi
dimethyl
lysin
addit
studi
demonstr
methyl
protein
produc
novel
crystal
form
differ
unmodifi
sampl
selenomethioninesubstitut
specimen
well
multimer
complex
amen
form
chemic
treatment
chemic
approach
purpos
crystal
remain
less
explor
although
recent
studi
demonstr
util
deliber
oxid
regard
work
bacteri
ppxgppa
phosphatas
homolog
kristensen
cowork
abl
obtain
two
uniqu
crystal
form
incub
protein
sampl
h
h
room
temperatur
prior
crystal
oxid
crystal
form
uniqu
found
exhibit
increas
physic
stabil
better
diffract
compar
crystal
form
obtain
untreat
sampl
mileston
crystal
structur
one
major
disappoint
regularli
encount
sbdd
program
employ
crystallographi
realiz
crystal
protein
target
poor
qualiti
unsuit
diffract
studi
phenomena
lowresolut
poorqual
diffract
eg
character
sever
mosaic
anisotropi
usual
stem
loos
molecular
pack
within
crystal
andor
high
intern
solvent
content
symptom
often
aris
crystal
otherwis
appear
physic
perfect
view
light
microscop
ad
research
frustrat
invari
lead
seriou
doubt
proceed
project
capitul
howev
sever
postcrystal
treatment
hand
improv
diffract
qualiti
protein
crystal
sometim
drastic
success
method
current
employ
improv
diffract
qualiti
stage
crystal
dehydr
crystal
anneal
latter
method
aros
way
repair
crystal
lattic
damag
inflict
flashcool
techniqu
rapid
cool
crystal
cryogen
temperatur
routin
use
limit
crystal
radiat
damag
induc
exposur
highintens
xray
sourc
crystal
anneal
involv
warm
flashcool
crystal
room
temperatur
follow
repeat
flash
cool
shown
improv
crystal
mosaic
diffract
resolut
method
crystal
dehydr
effect
reduc
crystal
solvent
content
enforc
tighter
crystal
pack
frequent
promot
remark
improv
diffract
qualiti
sever
dehydr
method
emerg
rang
slow
control
dehydr
crystal
droplet
period
day
week
quick
crystal
soak
dehydr
solut
minut
novel
devic
describ
allow
accur
control
crystal
water
content
regul
rel
humid
ga
stream
envelop
crystal
devic
avail
commerci
allow
diffract
properti
crystal
monitor
real
time
crystal
dehydr
diffract
improv
recent
studi
demonstr
method
fast
crystal
dehydr
coupl
crystal
anneal
lead
astonish
improv
diffract
qualiti
sometim
extend
diffract
limit
appar
worthless
crystal
specimen
nearli
tenfold
postcrystal
treatment
improv
diffract
resolut
includ
crystal
soak
crystal
crosslink
review
recent
mention
cryocrystallographi
method
choic
collect
diffract
data
highintens
xray
sourc
due
dampen
effect
diffus
harm
free
radic
crystal
allow
crystal
surviv
long
enough
xray
beam
collect
complet
singlecryst
highresolut
data
set
critic
object
cryocrystallographi
format
amorph
ice
within
around
crystal
upon
cryocool
crystallin
ice
format
yield
spuriou
diffract
obscur
use
protein
diffract
amorph
ice
format
facilit
addit
chemic
cryoprotect
glycerol
polyethylen
glycol
crystal
mother
liquor
sometim
crystal
mother
liquor
alreadi
contain
cryoprotect
formul
reagent
therebi
facilit
cryocool
crystal
directli
growth
solut
sever
commerci
crystal
screen
kit
contain
cryoreadi
reagent
develop
base
strategi
one
possibl
unwant
side
effect
regard
sbdd
howev
procliv
cryoprotect
molecul
appear
activ
site
enzym
case
screen
altern
cryoprotect
might
need
plausibl
workaround
elimin
need
convent
cryoprotect
use
cryoprotect
oil
paratonen
highli
liquid
paraffin
oil
work
form
protect
shield
around
crystal
anoth
cool
method
circumv
need
penetr
cryoprotect
highpressur
crystal
cool
first
explor
earli
recent
revisit
prototyp
pressur
devic
construct
cornel
high
energi
synchrotron
sourc
chess
allow
cryoloop
crystal
mount
highpressur
mpa
cryocool
preliminari
result
devic
shown
signific
improv
diffract
qualiti
protein
crystal
studi
encourag
protein
crystal
grown
reproduc
highqual
crystal
form
suitabl
sbdd
next
major
bottleneck
find
solut
phase
problem
coordin
relat
homolog
domain
avail
modelbas
phase
use
molecular
replac
method
prefer
strategi
rel
speed
modern
molecular
replac
softwar
implement
improv
search
featur
likelihoodenhanc
rotat
translat
function
improv
procedur
construct
molecular
replac
search
model
burgeon
pdb
databank
macromolecular
structur
data
liter
push
boundari
accomplish
method
preexist
structur
data
absent
insuffici
molecular
replac
phase
method
must
employ
histor
commonli
use
structuresolv
techniqu
multipl
isomorph
replac
mir
reli
prepar
deriv
crystal
one
type
heavi
atom
bound
specif
uniformli
macromolecul
within
crystal
outcom
mir
method
addit
conting
heavyatom
deriv
truli
isomorph
ie
bear
extrem
limit
alter
molecular
structur
unitcel
dimens
success
phase
determin
mir
consequ
ratelimit
speed
suitabl
heavyatom
deriv
obtain
advanc
multiplewavelength
anomal
dispers
phase
construct
tunabl
synchrotron
xray
beamlin
worldwid
made
multiplewavelength
anomal
dispers
method
choic
experiment
phase
determin
particularli
highthroughput
ht
sbdd
applic
one
big
advantag
multiplewavelength
anomal
dispers
phase
offer
mir
relat
method
sira
mira
singl
multipleisomorph
replac
anomal
scatter
reduct
systemat
error
sinc
data
measur
singl
sampl
result
phase
angl
therefor
accur
determin
result
electron
densiti
map
typic
higher
qualiti
map
calcul
phase
deriv
isomorph
method
multiplewavelength
anomal
dispers
phase
requir
presenc
suitabl
number
atom
xray
absorpt
edg
energi
rang
easili
access
tunabl
synchrotron
sourc
typic
l
multiplewavelength
anomal
dispers
phase
experi
carri
use
selenomethioninesubstitut
semet
protein
although
sometim
semet
multiplewavelength
anomal
dispers
phase
inappropri
method
phase
determin
situat
multiplewavelength
anomal
dispers
phase
carri
bound
element
atom
number
synchrotronaccess
absorpt
edg
element
often
found
natur
metal
cofactor
protein
transit
metal
diffus
protein
crystal
use
convent
heavyatom
soak
method
prescreen
degre
semet
heavi
atom
incorpor
target
protein
rapidli
carri
mass
spectrometri
altern
nativ
polyacrylamid
gel
electrophoresi
experi
allow
quick
simpl
assess
heavi
atom
bind
optim
bind
concentr
impact
protein
stabil
explor
novel
approach
introduc
anomal
scatter
element
protein
crystal
purpos
multiplewavelength
anomal
dispers
phase
led
robust
collect
new
phase
altern
exampl
chemic
modifi
ligand
use
ration
phase
tool
halogen
nucleotid
multiplewavelength
anomal
dispers
phase
nucleotidebind
protein
seleniumsubstitut
saccharid
carbohydratebind
protein
multiplewavelength
anomal
dispers
phase
krypton
demonstr
feasibl
techniqu
cryosoak
halid
monoand
polyval
cation
sever
uniqu
procedur
produc
deriv
appear
year
continu
explor
field
sure
gener
addit
phase
altern
moreov
modern
develop
area
util
soft
xray
l
sulfurbas
anomal
phase
techniqu
pioneer
year
ago
hendrickson
teeter
structur
determin
crambin
may
eventu
circumv
need
derivat
case
altogeth
crystal
structur
particular
target
solv
sbdd
begin
crystal
form
thoroughli
scrutin
presenc
characterist
patholog
might
prolong
even
prohibit
design
process
diffract
resolut
high
enough
ie
resolut
prefer
bar
aforement
problem
crystallograph
pursu
number
integr
strategi
gener
harvest
highli
valu
structur
data
stage
integr
effort
crystallograph
model
medicin
chemist
overemphas
earli
collabor
undoubtedli
speed
progress
hit
lead
lead
compound
therapeut
potenti
figur
convent
approach
lead
discoveri
involv
screen
target
highthroughput
screen
ht
librari
see
highthroughput
highcont
screen
ht
librari
contain
upward
million
compound
therefor
implicitli
requir
highthroughput
method
make
time
scale
process
manag
biochem
assay
amen
high
throughput
normal
devis
screen
compound
ic
mm
typic
select
test
see
optic
assay
drug
discoveri
fluoresc
screen
assay
cellbas
screen
assay
hit
may
hand
medicin
chemist
optim
potenc
druglik
properti
deliv
crystallograph
structur
character
target
ligand
complex
given
resourc
investigatori
avenu
might
pursu
concurr
therefor
vital
crystallograph
keep
apac
medicin
chemist
iter
natur
sbdd
cycl
design
synthesi
bioassay
follow
crystal
structur
determin
target
ligand
complex
requir
individu
disciplin
work
effect
one
anoth
see
structurebas
drug
design
use
protein
structur
drug
discoveri
iter
approach
appli
sbdd
sever
way
power
techniqu
de
novo
drug
design
design
novel
chemic
structur
scratch
guid
crystal
structur
empti
activ
site
see
de
novo
design
anoth
strategi
lead
optim
begin
crystal
structur
target
lead
complex
lead
may
discov
chemic
patent
literatur
ht
compound
librari
sourc
de
novo
design
complex
lead
target
protein
elucid
crystallograph
lead
modifi
order
optim
chemic
biolog
properti
see
absorpt
distribut
metabol
excret
toxic
research
crystallograph
fundament
compon
design
cycl
success
structur
determin
complex
high
resolut
complex
obtain
target
ligand
cocrystal
diffus
ligand
preform
crystal
soak
method
particular
strength
weak
soak
take
advantag
fact
macromolecular
crystal
solvent
rich
contain
integr
network
solvent
channel
howev
size
configur
channel
within
crystal
lattic
place
upper
limit
size
ligand
may
diffus
usual
issu
small
druglik
molecul
mention
crystal
lattic
restraint
sometim
hinder
conform
rearrang
target
might
necessarili
coincid
ligand
bind
hand
rearrang
take
place
may
disrupt
crystal
lattic
caus
irrevers
damag
cocrystal
approach
target
ligand
complex
form
crystal
carri
alter
physicochem
properti
complex
rel
nativ
protein
may
preclud
crystal
complex
nativ
condit
herein
lie
perceiv
advantag
soak
method
nativ
crystal
grown
reproduc
conserv
isomorph
nativ
soak
crystal
allow
rapid
detect
bound
ligand
differ
fourier
method
mean
cocrystal
method
less
amen
highthroughput
sbdd
contrari
plexxikon
group
recent
demonstr
effect
cocrystal
approach
sbdd
program
target
human
phosphodiesteras
ligand
soak
cocrystal
practic
consider
order
compound
valu
sbdd
must
present
high
enough
concentr
crystal
drop
promot
high
occup
bind
target
therefor
produc
interpret
electron
densiti
sourc
difficulti
limit
ligand
solubl
impos
constraint
bind
occup
limit
use
crystallograph
data
someth
known
target
ligand
dissoci
constant
k
problem
approach
use
formula
ligand
protein
case
maximum
bind
occup
achiev
ad
slight
molar
excess
ligand
hand
protein
crystal
low
concentr
andor
low
affin
ligand
use
ie
k
protein
nk
term
becom
appreci
gener
guidelin
use
n
valu
least
although
trialanderror
come
play
ad
complic
calcul
reli
assumpt
measur
k
assay
condit
similar
k
crystal
drop
like
untru
polar
ligand
high
salt
concentr
normal
rais
k
crystal
drop
opposit
true
nonpolar
ligand
potenti
ad
puzzl
effect
cryoprotect
cosolv
polyethylen
glycol
known
sometim
interfer
ligand
bind
compet
ligandbind
site
consid
better
philosophi
ligand
soak
often
adher
howev
poorli
solubl
ligand
may
requir
use
suitabl
organ
solvent
dimethyl
sulfoxid
dmso
ethanol
methanol
hexafluoropropanol
crystallographi
fragonom
emerg
area
fragmentbas
drug
design
novel
approach
drug
discoveri
develop
recent
util
biophys
method
screen
collect
basic
chemic
build
block
term
fragment
see
fragmentbas
approach
fragment
librari
tend
contain
compound
therefor
much
smaller
convent
ht
librari
compound
also
smaller
simpler
averag
molecular
weight
da
nonhydrogen
atom
typic
ht
compound
consequ
fragment
bind
target
protein
weakli
affin
detect
limit
convent
ht
method
biophys
techniqu
nmr
see
nuclear
magnet
reson
drug
discoveri
xray
crystallographi
howev
power
screen
method
fragmentbas
search
gener
accept
target
fragment
interact
low
millimolar
k
reliabl
detect
use
nmr
xray
crystallographi
xraybas
screen
ad
advantag
inher
produc
highresolut
structur
data
provid
basi
comput
design
medicin
chemistri
decis
constitut
good
fragment
librari
analysi
fragment
hit
varieti
target
led
astex
group
formul
rule
three
describ
typic
fragment
hit
molecular
weight
da
hydrogen
bond
donor
hydrogen
bond
acceptor
octanolwat
partit
coeffici
log
p
number
rotat
bond
first
wellpublic
crystal
screen
method
term
crystallead
develop
abbott
lab
practic
applic
method
initi
demonstr
anticanc
target
urokinas
studi
shapedivers
compound
mixtur
soak
crystal
engin
form
protein
term
microurokinas
section
four
mixtur
yield
evid
bind
five
novel
ligand
one
mixtur
contain
two
binder
less
potent
ligand
discov
rescreen
potent
inhibitor
remov
firstround
optim
one
lead
result
increas
inhibitor
potenc
k
mm
nm
provid
favor
start
point
lead
develop
demonstr
success
fragmentbas
method
bolster
explor
develop
approach
plexxikon
group
recent
introduc
crystallographydriven
screen
techniqu
call
scaffoldbas
drug
design
implement
program
develop
novel
inhibitor
human
phosphodiesteras
pde
accord
plexxikon
definit
main
differ
librari
contain
molecular
scaffold
vs
molecular
fragment
former
compris
slightli
larger
molecul
averag
molecular
weight
da
contain
addit
function
group
enabl
bind
target
affin
detect
convent
ht
approach
preliminari
ht
assay
use
compound
concentr
mm
initi
select
candid
target
protein
crystal
presenc
mm
scaffold
molecul
rang
ph
precipit
addit
screen
help
increas
chanc
cocrystal
author
report
overal
cocrystal
success
rate
chemic
scaffold
select
structur
studi
differ
pde
scientist
sunesi
develop
proprietari
fragmentbas
method
call
tether
offer
sitedirect
mean
probe
ligand
bind
target
tether
take
advantag
nativ
engin
surfaceexpos
cystein
target
captur
thiolcontain
ligand
format
mix
disulfid
crystallograph
analysi
coval
link
complex
provid
power
mean
rapid
identif
fragment
convert
revers
inhibitor
exemplifi
group
develop
novel
alloster
activesit
caspas
inhibitor
lead
identif
interact
fragment
target
character
crystallograph
method
iter
structuredriven
chemistri
appli
gener
drugsiz
lead
compound
see
fragmentbas
approach
subsequ
step
subdivid
four
distinct
categori
fragment
optim
fragment
link
fragment
evolut
fragment
selfassembl
figur
fragment
evolut
lead
molecul
iter
gener
evolv
build
away
start
fragment
region
bind
pocket
fragment
link
defin
process
chemic
join
two
fragment
bind
adjac
site
gener
larger
compound
greater
potenc
fragment
optim
involv
alter
properti
lead
molecul
includ
select
efficaci
sar
xray
approach
method
fragment
selfassembl
util
mixtur
fragment
adorn
reactiv
group
socal
dynam
combinatori
librari
link
togeth
situat
close
proxim
eg
within
target
activ
site
see
dynam
ligand
assembl
way
target
catalyz
synthesi
presum
highest
affin
lead
librari
fragment
xrayguid
extens
fragment
selfassembl
term
dynam
combinatori
xray
crystallographi
dcx
allow
selfassembl
lead
gener
dynam
combinatori
librari
presenc
protein
crystal
permit
direct
observ
bind
interact
target
figur
fragmentbas
lead
gener
optim
approach
fragment
link
involv
join
fragment
identifi
vicin
bind
site
chemic
linker
lead
larger
molecul
higher
bind
affin
b
fragment
evolut
proce
iter
build
singl
start
fragment
creat
larger
complex
molecul
interact
neighbor
pocket
c
fragment
optim
entail
ration
reengin
lead
molecul
order
improv
alter
specif
properti
molecul
eg
affin
select
oral
bioavail
fragment
selfassembl
exploit
abil
reactiv
fragment
complementari
function
group
assembl
larger
potent
molecul
situat
proxim
bind
pocket
target
templat
era
highthroughput
crystallographi
lead
discoveri
past
determin
protein
xray
crystal
structur
typic
requir
sever
year
difficult
case
even
decad
main
bottleneck
obtain
suitabl
amount
pure
protein
sampl
drastic
reduc
advent
molecular
biolog
tool
develop
see
protein
product
threedimension
structur
analysi
structur
determin
process
tradit
lengthi
labori
undertak
greatli
benefit
sweep
technolog
methodolog
breakthrough
advanc
task
autom
miniatur
parallel
usher
new
era
highthroughput
crystallographi
origin
notion
highthroughput
crystallographi
conceiv
pharmaceut
sector
diminish
interest
xray
crystallographi
instead
focus
ht
technolog
structur
genom
initi
establish
goal
solv
crystal
structur
repres
known
protein
famili
see
structur
genom
ambiti
goal
bore
immedi
need
establish
new
methodolog
produc
hundr
protein
parallel
creat
ht
system
dispens
monitor
thousand
crystal
experi
per
day
determin
result
xray
structur
fulli
autom
fashion
technolog
advanc
emerg
variou
structur
genom
initi
help
improv
understand
protein
fold
space
also
substanti
benefit
pharmaceut
industri
ad
xray
crystallographi
preexist
armamentarium
ht
tool
drug
discoveri
design
dna
construct
genom
approach
usual
taken
outset
bioinformat
tool
use
mine
avail
databas
homolog
sequenc
variou
organ
multiplesequ
align
examin
predict
possibl
domain
structur
protein
see
bioinformat
sever
ortholog
gener
differ
startstop
point
delin
domain
interest
appropri
oligonucleotid
primer
either
synthes
order
en
mass
microtit
plate
typic
higher
use
autom
htpcr
clone
test
express
attain
largescal
autom
product
purif
protein
demonstr
construct
elabor
robot
system
capabl
handl
parallel
ml
bacteri
cultur
averag
yield
mg
purifi
protein
per
sampl
bacteri
cellfre
system
base
e
coli
extract
offer
opportun
autom
product
milligram
quantiti
protein
test
tube
robot
system
autom
crystal
smaller
volum
higher
densiti
plate
configur
format
along
imag
system
autom
crystal
drop
monitor
score
enabl
ht
crystal
miniatur
scale
result
drastic
reduct
space
materi
cost
hardwar
softwar
solut
autom
crystal
mount
align
data
collect
allow
rapid
unman
data
collect
synchrotron
laboratori
sourc
softwar
develop
autom
macromolecular
structur
determin
enabl
rapid
seamless
transfer
diffract
data
process
phase
modelbuild
pipelin
ad
new
program
provid
solut
automat
gener
ligand
coordin
topolog
autom
ligand
build
electrondens
map
continu
develop
ht
crystallographi
hardwar
softwar
applic
global
integr
individu
process
hasten
lead
identif
optim
cycl
